Frequently Asked Questions
The Syndromic Multiplex Diagnostic Market size will be worth USD 5.05 billion by 2031 during the forecast period.
The Syndromic Multiplex Diagnostic Market growth rate is 6.1% during the forecast period.
The Rising Incidence of Infectious Diseases, Advancements in Diagnostic Technologies, Demand for Rapid and Accurate Diagnostics are the growth drivers of the Syndromic Multiplex Diagnostic Market.
The product and services, infection type, disease, panels type and end user are the factors on which the Syndromic Multiplex Diagnostic Market research is based.
The major companies in the Syndromic Multiplex Diagnostic Market are BioFire Diagnostics (A Subsidiary of bioMérieux SA), Seegene Inc. (South Korea), Luminex Corporation. A DiaSorin Company (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), BD (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Cepheid (A subsidiary of Danaher (U.S.)), QIAGEN (Germany), Abbott (U.S.), Hologic, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Siemens Healthcare GmbH (Germany), Akonni Biosystems, Inc. (U.S.), Biocartis (Belgium), QuantuMDx Group Ltd. (U.K.), Bosch Healthcare Solutions GmbH (A Subsidiary Of Robert Bosch GmbH) (Germany), Applied BioCode, Inc. (U.S.), Prominex Inc. (U.S.), Nanomix, Inc. (U.S.), Curetis (A subsidiary of OpGen, Inc.) (Germany), MiRXES Pte Ltd (Singapore).
